China's Fourth Domestic Player! Chia Tai Tianqing Launches $800M Anti-Cancer Drug Sunitinib Malate Capsules

On May 24, the official website of the National Medical Products Administration (NMPA) showed that Sunitinib Malate Capsules from Chia Tai Tianqing Pharmaceutical Group Co., Ltd. were approved for marketing, marking the fourth China-produced product to receive approval. Data from Menet indicates that Pfizer's Sunitinib Malate Capsules recorded global sales exceeding USD 800 million in 2020. In the same year, the combined sales of sunitinib capsules at public medical institution terminals and urban physical pharmacy terminals in China surpassed RMB 600 million.

Source: MENET One-Click Search

Available information indicates that Sunitinib Malate Capsules, developed by Pfizer, are indicated for the treatment of inoperable advanced renal cell carcinoma, gastrointestinal stromal tumors (GIST) after disease progression on or intolerance to imatinib mesylate, and unresectable metastatic well-differentiated progressive pancreatic neuroendocrine tumors.

Sales of Sunitinib Capsules in Public Medical Institutions and Urban Retail Pharmacies in China

Source: MENET Database

Data from Menet indicates that global sales of Pfizer's Sunitinib Malate Capsules exceeded USD 800 million in 2020. In 2020, the combined sales of sunitinib capsules at terminals of urban public hospitals, county-level public hospitals, urban community centers, and township health centers in China (hereinafter referred to as Chinese public medical institutions) and at urban physical pharmacy terminals in China surpassed RMB 600 million. Among these, urban physical pharmacy terminals recorded the fastest growth, with a year-on-year increase of nearly 70%.

Currently, there are five manufacturers of Sunitinib Malate Capsules. Among them, four domestic pharmaceutical enterprises, including CSPC Ouyi Pharmaceutical, Hunan Kelun Pharmaceutical, and Chia Tai Tianqing Pharmaceutical Group Co., Ltd., have all been approved as Class 4 generics and are deemed to have passed the consistency evaluation. Additionally, the Class 4 generic marketing application for Sunitinib Malate Capsules submitted by Qilu Pharmaceutical (Hainan) is currently under review and approval at the Center for Drug Evaluation (CDE).

Source: NMPA Official Website, MENET Database